Pharmaceutical

Teva and mAbxience partner to develop biosimilar candidate for oncology

Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate.

Oct 6, 2024 - 04:00
Teva and mAbxience partner to develop biosimilar candidate for oncology
Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate.
Read the original article

Tags:

Previous Article

Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo

Next Article

BMS receives FDA approval for Opdivo to treat NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Could private equity be the future of private practice? A new lobbying group thinks so

STAT+: Could private equity be the future of private pr...

Jan 16, 2024

STAT+: California judge deals GSK a setback as first Zantac lawsuit will now go to trial

STAT+: California judge deals GSK a setback as first Za...

Mar 24, 2023

Takeda, Janssen join wearable maker to measure scratching, and other health tech news

Takeda, Janssen join wearable maker to measure scratchi...

Dec 1, 2023